Hadziev S, Kavaklieva-Dimitrova J
Neoplasma. 1977;24:225-31.
BCG has successfuly been applied in lymphoid and in myeloid leukemia but no positive results have been demonstrated in solid tumors except malignant melanoma after intratumoral injection. The authors' approach consists in applying BCG as an only antitumor treatment, much smaller doses and in much longer intervals between them than used by other investigators. The analysis of the treatment schemes of BCG, applied to 171 lung cancer patients showed that positive responses have been obtained only in patients without peripheral dissemination of the disease and that in doses from 0.0001 mg to 0.05 mg. The results obtained depended on the frequency of BCG application: the 5 years survival rate, the mean survival period and the rate of the marked X-ray regression have been found best in patients treated once, good in patients treated in intervals longer than 30 days between the applications of the mycobacteria and worse in patients treated in intervals shorter than 20 days. A direct inverse correlation has been discovered between the mean survival period of the treated patients and the number of the applications of BCG in the first 6 months of the treatment.
卡介苗已成功应用于淋巴性白血病和髓性白血病，但除了瘤内注射后的恶性黑色素瘤外，在实体瘤中尚未显示出阳性结果。作者的方法是将卡介苗作为唯一的抗肿瘤治疗方法，使用的剂量比其他研究者小得多，且两次用药之间的间隔长得多。对171例肺癌患者应用卡介苗的治疗方案分析表明，仅在疾病无外周扩散且剂量为0.0001毫克至0.05毫克的患者中获得了阳性反应。所获得的结果取决于卡介苗的应用频率：发现单次治疗的患者5年生存率、平均生存期和明显的X线消退率最佳，在两次应用分枝杆菌之间间隔超过30天治疗的患者中良好，而在间隔短于20天治疗的患者中较差。在治疗的前6个月中，已发现治疗患者的平均生存期与卡介苗的应用次数之间存在直接的负相关。
